TruSight Oncology 500 Portfolio
TruSight Oncology 500 Assay
Now with HRD* *Not available in Japan
Assess relevant DNA and RNA cancer biomarkers from FFPE tumor tissue, now including HRD through an accessory kit to assess the Genomic Instability Score (GIS).
TruSight Oncology 500 High-Throughput Assay
Batch up to 192 samples at a time while using the same panel content and tissue input type as the TruSight Oncology 500 assay.
TruSight Oncology 500 ctDNA v2 Assay
Analyze circulating tumor DNA (ctDNA) from blood plasma with a more sensitive and streamlined assay in <4 days with automation-friendly options.
Benefits of TruSight Oncology 500 Portfolio
Enable Comprehensive Genomic Profiling
Bring the Assay into Your Lab
Integrated, Flexible, and Scalable Workflow
Achieve Timely and Reliable Results
TruSight Oncology 500 Portfolio Brochure
This brochure provides an overview of the TSO 500 product portfolio. You'll learn about Its broad coverage, integrated workflows, automation capabilities, easy-to-use data analysis and more. Take cancer from uncertainty to insight with streamlined solutions enabling high-quality cmprehensive genomic profiling.
Download TSO 500 Portfolio BrochureTruSight Oncology 500 Portfolio News
Learn about portfolio updates that enable a simpler, faster, and more scalable samples-to-results workflow to enable comprehensive genomic profiling in your lab.
HRD Assessment
Maximize tumor insights by enabling comprehensive genomic profiling with the added value of Homologous Recombination Deficiency (HRD) assessment. HRD is available for TruSight Oncology 500*
*Not available in Japan
Improved ctDNA assessment with next gen assay
TruSight Oncology 500 ctDNA v2 brings more sensitive ctDNA analysis from blood with advanced chemistry to offer a more streamlined sample-to-answer workflow in <4 days.
Better variant calling with DRAGEN
DRAGEN technology improves TSO 500 variant calling by 50-80% and is even more streamlined on Illumina Connected Analytics (ICA) with in-run data streaming and auto-launch capabilities.
Variant interpretation options
Multiple options for variant interpretation and reporting with automated data ingestion for efficient analysis workflow.
†NovaSeq 6000Dx System in RUO Mode requires a separate, stand-alone DRAGEN server for secondary analysis.
‡Coming soon in 2024.
Pan-Cancer Biomarkers
Detection of currently relevant DNA & RNA* variants for multiple types of solid tumors. Some key biomarkers include:
| Pan-cancer: BRAFNTRK1 NTRK2 NTRK3RET MSI TMB | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Genes with biomarkers of significance† | Genes with biomarkers of potential significance‡ | ||||||||||
 Breast |
BRCA1 | BRCA2 | ERBB2 | ESR1 | PALB2 | PIK3CA | 180 | ||||
 Colorectal |
ERBB2 | KRAS | NRAS | 166 | |||||||
 Bone |
EGFR | ERG | ETV1 | ETV4 | EWSR1 | FEV | FLI1 | FUS | H3F3A | 140 | |
| HEY1 | IDH1 | MDM2 | NCOA2 | SMARCB1 | |||||||
 Lung |
ALK | EGFR | ERBB2 | KRAS | MET | NUTM1 | ROS1 | 223 | |||
 Melanoma |
KIT | NRAS | ROS1 | 172 | |||||||
 Ovarian |
BRCA1 | BRCA2 | FOXL2 | 149 | |||||||
 CNS |
APC | ATRX | CDKN2A | CDKN2B | EGFR | H3F3A | HIST1H3B | HIST1H3C | IDH1 | 140 | |
| IDH2 | MYCN | PTCH1 | RELA | TERT | TP53 | ||||||
 Prostate |
AR | ATM | BARD1 | BRCA1 | BRCA2 | BRIP1 | CDK12 | CHEK1 | CHEK2 | 151 | |
| FANCL | FGFR2 | FGFR3 | PALB2 | RAD51B | RAD51C | RAD51D | RAD54L | ||||
 Thyroid |
HRAS | KRAS | NRAS | RET | TERT | 165 | |||||
 Uterine & cervical |
BRCA2 | EPC1 | ERBB2 | ESR1 | FOXO1 | GREB1 | JAZF1 | NCOA2 | NCOA3 | 138 | |
| NUTM2A | NUTM2B | PAX3 | PAX7 | PHF1 | POLE | SMARCA4 | SUZ12 | TP53 | |||
| YWHAE | |||||||||||
 Other Solid Tumors |
ALK | APC | ARID1A | ASPSCR1 | ATF1 | ATIC | BAP1 | BCOR | BRCA1 | 152 | |
| BRCA2 | CAMTA1 | CARS | CCNB2 | CDK4 | CDKN2A | CIC | CITED2 | CLTC | |||
| COL1A1 | COL6A3 | CREB1 | CREB3L1 | CREB3L2 | CSF1 | CTNNB1 | DDIT3 | DDX3X | |||
| DNAJB1 | DUX4 | EED | EGFR | ERBB2 | ERG | ETV1 | ETV4 | ETV6 | |||
| EWSR1 | FEV | FGFR2 | FGFR3 | FLI1 | FOXL2 | FOXO1 | FOXO4 | FUS | |||
| GLI1 | HEY1 | HGF | HMGA2 | IDH1 | KRAS | LEUTX | MAML3 | MDM2 | |||
| MYB | MYOD1 | NAB2 | NCOA2 | NF1 | NFATC2 | NFIB | NR4A3 | NRAS | |||
| NUTMI | NUTM2A | NUTM2B | PALB2 | PATZ1 | PAX3 | PAX7 | PDGFB | PDGFRA | |||
| PRKACA | PRKD1 | RANBP2 | ROS1 | SDHA | SDHB | SDHC | SDHD | SMARCB1 | |||
| SS18 | SSX1 | SSX2 | SSX4 | STAT6 | SUZ12 | TAF15 | TCF12 | TERT | |||
| TFE3 | TFEB | TFG | TP53 | TPM3 | TPM4 | TRAF7 | TSPAN31 | VGLL2 | |||
| WT1 | WWTR1 | YAP1 | YWHAE | ZC3H7B | |||||||
The genes and biomarkers listed in this table are a subset of all genes included in the panel. To see the full gene list, view the product datasheet, available under Product Literature on the respective product pages.
* RNA variants only called from TSO 500 and TSO 500 HT assays.
† The product to evaluate DNA & RNA variants is the TruSight Oncology 500 DNA/RNA Bundle.
Analytical Evaluation & Verification Service
The TruSight Oncology 500 Analytical Evaluation Service facilitates alignment with the latest CAP, AMP, and European standards. Use the service to evaluate analytical performance characteristics and integrate products into your workflows while reducing overall evaluation time by ~60%.
View ServiceTruSight Oncology 500 Portfolio Resources
TruSight Oncology ctDNA 500 v2
Illumina has improved the analysis of solid tumors from circulating tumor DNA (ctDNA) with TruSight Oncology 500 ctDNA v2. Learn about the new features and benefits in the video.
Research Collaboration with National Center Japan
TruSight Oncology 500 ctDNA panel to be used for research into personalized cancer treatments for Nasopharyngeal Carcinoma.
Illumina Partners to Advance Precision Medicine Approach for Late-Stage Cancer Patients
CELIA research study will assess value of CGP with the Illumina TruSight Oncology 500 assay versus standard of care in the French health care system.
NTRK Fusion Detection for Identification of Rare Genomic Events
NTRK fusions are rare but important biomarkers linked to response to TRK inhibitors. Watch CMO Phil Febbo and Maude Champagne walk through these advances in fusion detection.